Key points:
- Two medical technology companies are reportedly in agreement on the economic terms of the merger.
- A dispute over executive leadership ended negotiations for this $34 billion deal.
- This failed transaction highlights the critical importance of corporate control in mergers and acquisitions.
Two medical technology companies reportedly reached agreement on the financial terms of a $34 billion merger. They had negotiated over equity, valuation, and even a multi-billion-dollar payment. However, the deal ultimately fell apart over an issue neither side was willing to compromise on: who would become CEO?
The proposed merger involves Johnson & Johnson’s orthopedics business, DePuy Synthes, and the UK medical device manufacturer Smith & Nephew. According to a Financial Times investigation on October 23, negotiations broke down weeks before the planned announcement.
This reminds us that even massive corporate acquisitions depend on decisions that cannot be resolved by financial calculations alone.
A $34 billion transaction in which nearly all matters have been finalized
Smith & Nephew approached Johnson & Johnson in early 2026 with a proposal to merge its business with DePuy Synthes, one of the world’s largest manufacturers of artificial joints and orthopedic devices.
The proposed transaction values Johnson & Johnson's division at approximately $22 billion, while Smith & Nephew's market capitalization is approximately $12.6 billion.
Smith & Nephew will also arrange approximately $10 billion in debt financing to pay Johnson & Johnson, helping to balance the valuation differences between the two companies.
This transaction would have combined complementary hip and knee replacement product portfolios, creating greater scale for both companies.
But as with other abandoned mergers and acquisitions, financial logic does not necessarily guarantee that both parties will agree on the final deal.
The CEO who left in 2019 has returned to the negotiating table.
The disagreement centers on two executives: Namal Nawana and Deepak Nath.
Nawana served as CEO of Smith & Nephew for approximately 18 months before leaving in 2019 amid compensation disputes. Six years later, he joined Johnson & Johnson to lead DePuy Synthes in advancing its planned spin-off.
According to sources, Johnson & Johnson hopes that Nawana will serve as CEO of the combined company. However, Smith & Nephew insists that current CEO Deepak Nath retain the top position.
Chairman Rupert Soames is said to have made Nath's appointment as CEO a condition of the deal.
This dispute illustrates why corporate governance can determine the success or failure of a multi-billion-dollar transaction.
This issue becomes especially challenging when two management teams have different visions for the company’s future.
What happens after the $34 billion merger fails?
Johnson & Johnson previously announced in October 2025 its plan to spin off DePuy Synthes, a business that generated approximately $9.2 billion in sales in 2024.
After negotiations failed, Johnson & Johnson stated it prefers to proceed with an independent spin-off plan.
This also shows that an acquisition offer that seems highly attractive may fall through even before investors receive a formal proposal.